|
7.11.08 ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
InSightec Ltd. is conducting an FDA approved phase III pivotal study (BM004) to evaluate the effectiveness and safety of ExAblate (MR guided Focused Ultrasound, MRgFUS) for the palliation of pain from metastatic bone tumors in patients who are not suitable candidates to receive additional radiation therapy. ExAblate MRgFUS uses (focused) ultrasound to treat tissue without surgical cutting (i.e. non-invasive procedure). The ExAblate use for the palliation of pain from bone metastases is experimental. The study hypothesis is that ExAblate is safe and effective in the treatment of pain resulting from metastatic bone tumors in patients that did not respond to radiation treatment or who are otherwise unsuitable for radiation treatment, with a low incidence of co-morbidity.
This clinical trial is open for enrollment at study sites nationwide.
Click Here for a study summary and a list of participating sites.
8.17.08 Clinical trial MDA-3410 is for men with Androgen Independent Prostate Cancer (AIPC)/Hormone Refractory Prostate Cancer (HRPC) that has spread to bone. The results of an earlier M.D. Anderson Cancer Center conducted clinical trial suggested that the addition of strontium chloride (Sr89) to a chemotherapeutic treatment regimen might improve outcomes for men with this stage of prostate cancer. This clinical trial will compare the effectiveness, in terms of overall survival, of therapy with or without strontium chloride (Sr89) after response to initial treatment with chemotherapy in men with AIPC/HRPC that has spread to bone.
This clinical trial is open for enrollment at study sites nationwide.
Click Here for a study summary that you can share with your healthcare team.
Click Here for a list of participating study sites.
3.30.2007 Duramed Research, Inc. is conducting a clinical research trial for the treatment of hot flashes in men with Prostate Cancer following surgical or medical
castration.
Learn more about this trial at here.
2.19.2007 Eastern Cooperative Oncology Group: E3805 Trial For Patients With Metastatic High Risk Prostate Cancer
This study is for prostate cancer patients whose disease has spread to four or more sites in the bones or to the liver. The standard of care for these patients is to give hormonal therapy and then observe, giving chemotherapy if the disease progresses or recurs. The trial is looking at the potential benefit of giving chemotherapy immediately after hormonal therapy.
Learn more about this trial and view a short informational video featuring Dr. Christopher Sweeney, the study chair for this trial
here.
2.19.2007 Novartis Oncology is conducting a clinical research study to evaluate the difference in effectiveness and safety between the investigational drug patupilone and the drug docetaxel, in people who have metastatic hormone refractory prostate cancer.
Read more here.
For more information regarding this trial as well as sites participating, please contact:
www.novartisclinicaltrials.com – select Prostate Cancer or call 1-800-340-6843 – The Novartis Oncology Clinical Trials Hotline
www.clinicaltrials.gov – In the search box enter patupilone
11.10.06 RESEARCH
STUDY: With funding from the National Cancer Institute,
Inflexxion is evaluating the effectiveness of a
telephone-based system to help physicians monitor and
manage their patient’s pain level and symptoms.
Participation involves using the system at home and
completing questionnaires. You must be 18 years old and
have prostate cancer. Takes 45 minutes to one hour over
two days. Reimbursement $80. Screening web page at: www.studiesforcancer.com.
Contact Liza Quinonez: lquinonez@inflexxion.com
or (800) 848- 3895 ext. 240. Read flyer here.
11.3.06 A new trial is currently recruiting men with prostate cancer whose PSA continues to rise despite hormone therapy. This clinical trial will investigate if denosumab (investigational medication) can delay the onset of bone metastasis (cancer spreading to your bones).
Please click here
if you would like additional information or visit http://www.Rising-PSA.com.
11.3.06 A new trial is currently recruiting men with hormone-refractory prostate cancer that have bone metastases. This clinical trial will investigate if denosumab (investigational medication) is effective in treating bone metastases as compared to a current therapy. Please
click here if you would like additional
information or visit http://www.Rising-PSA.com.
10.11.06 Bone Loss Related to Hormone Therapy-What To Do?
(RTOG 0518)
This past spring, the Radiation Therapy Oncology Group (RTOG), a national cooperative group funded by the National Cancer Institute (NCI), opened a clinical trial, RTOG 0518, to examine the problem of long-term hormone therapy can affect bone health and, in some patients, cause bone demineralization, or osteoporosis. The study is open to men who have been treated for “high risk” prostate cancer with any form of radiation therapy (external beam or brachytherapy) and have received more than one year of LHRH hormone therapy.
See here for more about eligibility requirements and other study information.
For more information please visit
www.rtog.org or contact
RTOG Headquarters at 800-227-5463 x 4189. The complete research protocol can be found
here.
10.4.06 A Phase I/II Study of Autologous Dendritic Cells Pulsed with Apoptotic Tumor Cells (DC/PC3) Administered Subcutaneously to Prostate cancer Patients (RDA 0537)
We are currently recruiting men with prostate cancer to participate in a clinical trial for a dendritic cell vaccine study at Rockefeller University in New York City. Please
click
here or contact Mayu Okawa Frank, ANP at (212) 327-7443 for more information.
8.9.06 FDA approves Phase III Clinical Study Using HIFU with the Sonablate(R) 500 for the Treatment of Prostate Cancer -- The clinical study will use High Intensity Focused Ultrasound (HIFU) for the treatment of low risk, localized (T1c/T2a) prostate cancer with the Sonablate® 500. The study will enroll approximately 466 subjects at 24 institutions.
Read more here
8.7.06 NCI currently conducting trials for patients with prostate cancer -- The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), conducts more than 150 clinical trials at the NIH Clinical Center in Bethesda, Md. NCI is currently conducting clinical trials for patients with prostate cancer.
Visit http://bethesdatrials.cancer.gov/prostate for a listing of prostate cancer clinical trials that are currently enrolling patients at the NIH Clinical Center.
There is no charge for medical care received at the NIH Clinical Center. Study participants will be responsible for travel costs for their initial screening visits. Once participants are enrolled in a trial, NCI will pay for the transportation costs for all subsequent trial-related visits for participants who do not live in the local area. In addition, these participants will receive a small per diem for food and lodging expenses if they are being treated as outpatients.
For more information on clinical trials conducted at NCI, please visit
http://bethesdatrials.cancer.gov or call the Clinical Trials Referral Office (formerly Clinical Studies Support Center) at 1-888-NCI-1937 (1-888-624-1937).
The National Cancer Institute also sponsors clinical studies at cancer centers nationwide. To learn more about these studies, call 1-800-4-CANCER (1-800-422-6237).
7.25.06 Nursing research study to learn more about the concerns that prostate cancer patients and their partners face during and after the experience of prostate cancer surgery -- The study involves interviewing prostate cancer patients and their spouse or partner about their experiences in person or by phone. They will be compensated $20.00 per interview for their time. All identifiable information is kept confidential. It is hoped that the information obtained from this study will aid nurses and physicians in understanding the patient and their partner's experience in order to help prostate cancer patients and their partners after treatment.
Read more here
7.28.06 Ablatherm® High Intensity Focused Ultrasound (HIFU) Clinical Trial
A phase III randomized, prospective, multi-center clinical study of High Intensity Focused Ultrasound (HIFU) for the treatment of low risk localized prostate cancer has been initiated in the United States. The objective of the study is to assess the safety and effectiveness of HIFU as compared to cryotherapy.
Read more here
5.19.06 ASCENT-2 is a pivotal Phase 3 clinical study evaluating the combination of DN-101, a novel oral anti-cancer agent, and
Taxotere® (docetaxel) in men with prostate cancer for whom hormonal therapy is no longer working, also known as androgen-independent prostate cancer (AIPC). This randomized, controlled, multi-national study is seeking to enroll approximately 900 patients at over 125 medical centers in the United States, and Canada. Patients, or physicians interested in referring a qualified patient, can now go to
www.ASCENT-2.com.
Read more here
3.5.06 Can exercise improve well-being for cancer survivors?
New study for cancer survivors recently opened at the NIH’s National Center for Complementary and Alternative Medicine
(NCCAM): A Randomized Study of the Effect of Tai Chi Chuan Compared to a Structured Exercise Program on Parameters of Physical Fitness and Stress in Adult Cancer Survivors.
Read flyer here
11.17.05 New Study: How Do Couples Communicate with Each Other About Cancer?
If you are in a relationship with a spouse or partner and are receiving treatment or have been out of treatment for no more than two years, you may wish to consider taking part in this study. This study is open to both patients and their spouses. It would take no more than 15 minutes of your time to complete a questionnaire.
Read more & find out how to participate here
|
